MedTrace Logo

Pharmacokinetics and Safety of AmBisome and DKF-5122

NCT05749380 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-03-01

No results posted yet for this study

Summary

The purpose of the study is to assess the Safety and Pharmacokinetic Characteristics of AmBisome and DKF-5122

Conditions

  • Invasive Fungal Infections
  • Neutropenic Fever

Interventions

DRUG

AmBisome

Reference, dose of 3 mg/kg.

DRUG

DKF-5122

Test, dose of 3 mg/kg

Sponsors & Collaborators

  • Dongkook Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2022-01-28
Completion
2022-01-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749380 on ClinicalTrials.gov